Antidepressant-related erectile dysfunction: Management via avoidance, switching antidepressants, antidotes, and adaptation

Journal of Clinical Psychiatry

Volumn 64, Issue 10, 2003, Pages 11-19

  Labbate, Lawrence A ^c   Croft, Harry A ^a   Oleshansky, Marvin A ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b San Antonio Center for Clinical Research   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIDOTE; BETHANECHOL; BUSPIRONE; CITALOPRAM; CYPROHEPTADINE; DEXAMPHETAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; GINKGO BILOBA EXTRACT; GRANISETRON; METHYLPHENIDATE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; PEMOLINE; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN 2 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; YOHIMBINE;

ADAPTATION; CLINICAL TRIAL; DEPRESSION; DRUG CHOICE; DRUG EFFICACY; DRUG USE; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HUMAN; MALE; MEDLINE; ORGASM DISORDER; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

ANTIDEPRESSIVE AGENTS; BUPROPION; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER; DOXEPIN; DRUG TOLERANCE; HUMANS; IMPOTENCE; MALE; MIANSERIN; MOCLOBEMIDE; ORGASM; REMISSION, SPONTANEOUS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 0141633036     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Stahl SM. The psychopharmacology of sex, pt 1: neurotransmitters and the 3 phases of the human sexual response [BRAINSTORMS]. J Clin Psychiatry 2001;62:80-81
2. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57:1012-1030
3. Hull EM, Lorrain DS, Du J, et al. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav Brain Res 1999;105:105-116
4. Giuliano F, Allard J. Dopamine and male sexual function. Eur Urol 2001;40:601-608
5. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl 2000;113:37-45
6. Fabre-Nys C. Steroid control of monoamines in relation to sexual behaviour. Rev Reprod 1998;3:31-41
7. Angulo J, Peiro C, Sanchez-Ferrer CF, et al. Differential effects of serotonin reuptake inhibitors on erectile responses, NO-production, and neuronal NO synthase expression in rat corpus cavemosum tissue. Br J Pharmacol 2001;134:1190-1194
8. Montejo AL, Llorca G, Izquierdo JA, et al, for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62(suppl 3):10-21
9. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
10. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194
11. Nurnberg HG. Managing treatment-emergent sexual dysfunction associated with serotonergic antidepressants: before and after sildenafil. J Psychiatr Pract 2001;7:92-108
12. Mackay FR, Dunn NR, Martin RM, et al. Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 1999;49:892-896
13. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001;35:1608-1613
14. Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 2001;155:52-57
15. Fiorino DF, Phillips AG. Facilitation of sexual behavior in male rats following d-amphetamine-induced behavioral sensitization. Psychopharmacology (Berl) 1999;142:200-208
16. Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999;21:454-463
17. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-215
18. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040-1058
19. Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-658
20. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000;20:122-128
21. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532-537
22. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57 (suppl 2):53-62
23. Gardner EA, Johnston JA. Bupropion: an antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24-29
24. Clayton AH, McGarvey EL, Abouesh AI, et al. Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. J Clin Psychiatry 2001;62:185-190
25. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993;54:459-465
26. Rogoz Z, Wrobel A, Dlaboga D, et al. Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol 2002;54:381-389
27. Millan MJ, Gobert A, Rivet JM, et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin 2C receptors: a comparison with citalopram. Eur J Neurosci 2000;12:1079-1095
28. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998;51:267-285
29. Koutouvidis N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction. Int Clin Psychopharmacol 1999;14:253-255
30. Gelenberg AJ, Laukes C, McGahuey C, et al. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 2000;61:356-360
31. Owens MJ, Ieni JR, Knight DL, et al. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: in vivo and ex vivo studies. Life Sci 1995;57:PL373-PL380
32. Bagdy G, Kalogeras KT, Szemeredi K. Effect of 5-HT1C and 5-HT2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations. Eur J Pharmacol 1992;229:9-14
33. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-38
34. Ferguson JM, Shrivastava RK, Stahl SM, et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 2001;62:24-29
35. Schreiber S, Getslev V, Weizman A, et al. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neurosci Lett 1998;253:183-186
36. Atmaca M, Kuloglu M, Tezcan E, et al. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2003;18:277-280
37. Ramasubbu R. Switching to moclobemide to reverse fluoxefine-induced sexual dysfunction in patients with depression. J Psychiatry Neurosci 1999;24:45-50
38. Philipp M, Kohnen R, Benkert O. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993;7:149-153
39. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100
40. Philipp M, Tiller JWG, Baier D, et al, and the Australian and German Study Groups. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. Eur Neuropsychopharmacol 2000;10:305-314
41. Kennedy SH, Eisfeld BS, Dickens SE, et al. Anfidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-281
42. Balon R. Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Marital Ther 1996;22:290-292
43. Shrivastava RK, Shrivastava S, Overweg N, et al. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors [letter]. J Clin Psychopharmacol 1995;15:83-84
44. Gross MD. Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants. Am J Psychiatry 1982;139:1193-1194
45. Segraves RT. Reversal by bethanechol of imipramine-induced ejaculatory dysfunction [letter]. Am J Psychiatry 1987;144:1243-1244
46. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 1996;93:69-70
47. Steele TE, Howell EF. Cyproheptadine for imipramine-induced anorgasmia [letter]. J Clin Psychopharmacol 1986;6:326-327
48. McCormick S, Olin J, Brotman AW. Reversal of fluoxefine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry 1990;51:383-384
49. Amott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry 1994;164:838-839
50. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1995;18:320-324
51. Ashton AK, Ahrens K, Gupta S, et al. Antidepressant-induced sexual dysfunction and ginkgo biloba [letter]. Am J Psychiatry 2000;157:836-837
52. Balon R. Ginkgo biloba for antidepressant-induced sexual dysfunction? J Sex Marital Ther 1999;25:1-2
53. Cohen AJ, Barthk B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998;24:139-143
54. Aizenberg D, Gur S, Zemishlany Z, et al. Mianserin, a 5-HT2a/2c and alpha 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol 1997;20:210-214
55. Aizenberg D, Naor S, Zemishlany Z, et al. The serotonin antagonist mianserin for treatment of serotonin reuptake inhibitor-induced sexual dysfunction in women: an open-label add-on study. Clin Neuropharmacol 1999;22:347-350
56. Dolberg OT, Klag E, Gross Y, et al. Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. Psychopharmacology (Berl) 2002;161:404-407
57. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone [letter]. J Clin Psychiatry 1997;58:89
58. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment [letter]. J Clin Psychiatry 1999;60:260-261
59. Roeloffs C, Bartlik B, Kaplan PM, et al. Methylphenidate and SSRI-induced sexual side effects [letter]. J Clin Psychiatry 1996;57:548
60. Bartlik BD, Kaplan P, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors. J Sex Marital Ther 1995;21:264-271
61. Gitlin MJ. Treatment of sexual side effects with dopaminergic agents [letter]. J Clin Psychiatry 1995;56:124
62. Segraves RT. Reversing anorgasmia associated with serotonin uptake inhibitors [questions and answers]. JAMA 1991;266:2279
63. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992;53:119-122
64. Schiavi RC, White D, Mandeli J, et al. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav 1997;26:231-241
65. Aydin S, Odabas O, Ercan M, et al. Efficacy of testosterone, trazodone and hypnotic suggestion in the treatment of non-organic male sexual dysfunction. Br J Urol 1996;77:256-260
66. Ashton AK, Rosen RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry 1998;59:112-115
67. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
68. Labbate LA, Grimes JB, Hines A, et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry 1997;9:241-245
69. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-186
70. Masand PS, Ashton AK, Gupta S, et al. Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study. Am J Psychiatry 2001;158:805-807
71. Clayton AH, McGarvey EL, Warnock JK, et al. Bupropion SR as an antidote to SSRI-induced sexual dysfunction. Presented at the 40th annual meeting of the New Clinical Drug Evaluation Unit; May 30-June 2, 2000; Boca Raton, Fla
72. Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 1991;69:149-156
73. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994;2:109-112
74. Landen M, Björling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-668
75. Landen M, Eriksson E, Agren H, et al. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1999;19:268-271
76. 3 antagonist granisetron [letter]. J Clin Psychiatry 1997;58:496-497
77. Berk M, Stein DJ, Potgieter A, et al. Serotonergic targets in the treatment of antidepressant induced sexual dysfunction: a pilot study of granisetron and sumatriptan. Int Clin Psychopharmacol 2000;15:291-295
78. Nelson EB, Shah VN, Welge JA, et al. A placebo-controlled, crossover trial of granisetron in SRI-induced sexual dysfunction. J Clin Psychiatry 2001;62:469-473
79. Nurnberg HG, Levine PE. Spontaneous remission of MAOI-induced anorgasmia. Am J Psychiatry 1987;144:805-807
80. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85
81. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-1516
82. Hensley PL, Nurnberg HG. Formulary restriction of selective serotonin reuptake inhibitors for depression: potential pitfalls. Pharmacoeconomics 2001;19:973-982